|
|
Each tablet contains
Composition
Nevirapine.....................................................................
200 mg
Lamivudine
....................................................................150
mg
Stavudine........................................................................
30 mg
Indications
Progressive or advanced HIV infection, in combination with atleast
2 other antiretroviral drugs.
Description
Nevirapine binds directly to reverse transcriptase (RT) and blocks
the RNA-dependent and DNA-dependent DNA polymerase activities by
causing a disruption of the enzyme's catalytic site. The activity
of nevirapine does not compete with template or nucleoside
triphosphates.
Lamivudine is a cytosine analog. After lamivudine is
triphosphorylated, it inhibits HIV reverse transcription via viral
DNA chain termination and inhibits RNA- and DNA-dependent DNA
polymerase activities of reverse transcriptase.
The monophosphate form of lamivudine is incorporated into the
viral DNA by hepatitis B virus polymerase, resulting in DNA chain
termination.
Stavudine is an analog of thymidine. It is phosphorylated by
cellular kinases into active triphosphate. Stavudine triphosphate
inhibits the HIV reverse transcriptase by competing with natural
substrate, thymidine triphosphate. It also causes termination of
DNA synthesis by incorporating into it.
Simultaneous use of AZT is not recommended, as it can inhibit the
intracellular phosphorylation of stavudine. Other anti-HIV drugs
do not possess this property.
Dosage
Adult: 200mg once daily for first 14 days and if no rash appears
increase to 200mg twice daily.
Children: 2 months-8 years: 4mg/kg once daily for first 14 days
and then if no rash 7mg/kg twice daily (maximum:400mg daily) 8-16
years (below 50kg): 4mg once daily for 1st 14 days and then if no
rash, 4mg twice daily (maximum: 400mg daily) Over 50kg: Adult
dose.
Presentations
30 tablets
60 tablets
|
Quality
